How to select the optimal treatment for first line metastatic colorectal cancer

doi:10.3748/wjg.v20.i4.899

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6878)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

489

WORD

297

HTML

3838

Tables (1-4)

250

Sum=4874

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

917

Download

1087

Sum=2004

Jan 28, 2014 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jan 28, 2014; 20(4): 899-907
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.899

Table 3 Available treatment regimens for first-line metastatic colorectal cancer

Treatment intensity	Molecular factor	Regimens
Single agent		5FU/LVCapecitabin
Two-drug		Capecitabin/bevacizumab
Two-drug		FOLFOX/XELOXFOLFIRI/XELIRI
Three-drug	RAS wt	FOLFOX + panitumumabFOLFIRI + cetuximab
Three-drug	Independent of RAS status	FOLFOX/XELOX + bevacizumabFOLFIRI/XELIRI + bevacizumabFOLFOXIRI
Four-drug		FOLFOXIRI + bevacizumab

Combination chemotherapy with 5-fluorouracil, folinic acid (5FU/LV), and oxaliplatin (FOLFOX), or irinotecan (FOLFIRI) or both (FOLFOXIRI), or capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI).

Citation: Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol 2014; 20(4): 899-907
URL: https://www.wjgnet.com/1007-9327/full/v20/i4/899.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i4.899